EE200300476A - 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon - Google Patents

4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon

Info

Publication number
EE200300476A
EE200300476A EEP200300476A EEP200300476A EE200300476A EE 200300476 A EE200300476 A EE 200300476A EE P200300476 A EEP200300476 A EE P200300476A EE P200300476 A EEP200300476 A EE P200300476A EE 200300476 A EE200300476 A EE 200300476A
Authority
EE
Estonia
Prior art keywords
drug
alpha
methylpropiono
toluidide
pvp
Prior art date
Application number
EEP200300476A
Other languages
English (en)
Estonian (et)
Inventor
Kay Cahill Julie
Frances Bateman Nicola
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300476A publication Critical patent/EE200300476A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300476A 2001-04-02 2002-03-27 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon EE200300476A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number Publication Date
EE200300476A true EE200300476A (et) 2003-12-15

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300476A EE200300476A (et) 2001-04-02 2002-03-27 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon

Country Status (21)

Country Link
US (1) US20040138299A1 (de)
EP (1) EP1381358B1 (de)
JP (1) JP2004525164A (de)
KR (1) KR20030087048A (de)
CN (1) CN1536993A (de)
AT (1) ATE324886T1 (de)
BR (1) BR0208421A (de)
CA (1) CA2443040A1 (de)
CZ (1) CZ20032647A3 (de)
DE (1) DE60211139T2 (de)
EE (1) EE200300476A (de)
ES (1) ES2261655T3 (de)
HU (1) HUP0303454A3 (de)
IL (1) IL157955A0 (de)
IS (1) IS6970A (de)
MX (1) MXPA03008999A (de)
NO (1) NO20034386L (de)
NZ (1) NZ528284A (de)
PL (1) PL365330A1 (de)
SK (1) SK12032003A3 (de)
WO (1) WO2002080902A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3548566B2 (ja) * 2001-02-27 2004-07-28 アストラゼネカ アクチボラグ 医薬製剤
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
HUE033168T2 (en) 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosage regimen for selective SIP1 receptor agonist
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CA2815460C (en) 2011-01-13 2017-04-18 Bio-Pharm Solutions Co., Ltd. Process for preparation of phenyl carbamate derivatives
MX353024B (es) 2011-12-27 2017-12-18 Bio Pharm Solutions Co Ltd Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145502B1 (de) * 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermales abgabesystem mit rotigotin
ES3019912T3 (en) 2014-12-05 2025-05-21 Aragon Pharmaceuticals Inc Anticancer compositions
ES2839128T3 (es) 2014-12-05 2021-07-05 Aragon Pharmaceuticals Inc Composiciones anticancerosas
WO2016090098A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
EP1381358B1 (de) 2006-05-03
HUP0303454A3 (en) 2005-12-28
SK12032003A3 (sk) 2004-03-02
CN1536993A (zh) 2004-10-13
BR0208421A (pt) 2004-03-30
NO20034386L (no) 2003-11-28
ATE324886T1 (de) 2006-06-15
MXPA03008999A (es) 2004-02-12
EP1381358A1 (de) 2004-01-21
PL365330A1 (en) 2004-12-27
KR20030087048A (ko) 2003-11-12
NO20034386D0 (no) 2003-10-01
IL157955A0 (en) 2004-03-28
DE60211139T2 (de) 2007-03-01
JP2004525164A (ja) 2004-08-19
US20040138299A1 (en) 2004-07-15
IS6970A (is) 2003-09-29
CZ20032647A3 (cs) 2004-09-15
ES2261655T3 (es) 2006-11-16
DE60211139D1 (de) 2006-06-08
CA2443040A1 (en) 2002-10-17
WO2002080902A1 (en) 2002-10-17
NZ528284A (en) 2005-04-29
HUP0303454A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
EE200300476A (et) 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
AR032912A1 (es) Formulacion farmaceutica
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
IS6329A (is) Lyf til að meðhöndla illkynja æxli
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
SE0103424D0 (sv) Pharmaceutical formulation
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
SE0102440D0 (sv) New compound
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
SE0103839D0 (sv) Pharmaceutical formulation & product
MXPA04001912A (es) Aminobenzofenonas novedosas.
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0102887D0 (sv) New formulation
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
BRPI0414223A (pt) uso de extratos de gentiana lutea como um agente antimicrobiano
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ